Lam, Carolyn S. P. http://orcid.org/0000-0003-1903-0018
Docherty, Kieran F. http://orcid.org/0000-0002-5446-9969
Ho, Jennifer E. http://orcid.org/0000-0002-7987-4768
McMurray, John J. V. http://orcid.org/0000-0002-6317-3975
Myhre, Peder L.
Omland, Torbjørn
Article History
Received: 1 June 2023
Accepted: 25 August 2023
First Online: 9 October 2023
Competing interests
: C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Novo Nordisk and Roche Diagnostics; has received consulting fees from Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, Cytokinetics, Darma, EchoNous, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Quidel Corporation, Radcliffe Group, Recardio, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and is a cofounder and nonexecutive director of Us2.ai. The employer of K.F.D., the University of Glasgow, has been remunerated by AstraZeneca for work relating to clinical trials. K.F.D. has received speaker’s honoraria from AstraZeneca, Pharmacosmos and Radcliffe Cardiology, has served on an advisory board for Us2.ai and Bayer AG, served on a clinical endpoint committee for Bayer AG, and has received grant support from Boehringer Ingelheim, Roche Diagnostics and AstraZeneca (paid to the institution of K.F.D.). J.E.H. is supported by National Institutes of Health grants R01 HL134893, R01 HL140224, R01HL160003 and K24 HL153669. J.E.H. has also received past research funding from Bayer, AG. J.J.V.M. has received support from a British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217 and the Vera Melrose Heart Failure Research Fund; has received payments through Glasgow University from work on clinical trials, consulting and other activities from Amgen, AstraZeneca, Bayer, Cardurion, Cytokinetics, GlaxoSmithKline, KBP Biosciences and Novartis; has received personal consulting fees from Alnylam Pharma, Bayer, Bristol Myers Squibb, George Clinical PTY, Ionis Pharma, Novartis, Regeneron Pharma and River 2 Renal; has received personal lecture fees from Abbott, Alkem Metabolics, AstraZeneca, Blue Ocean Scientific Solutions, Boehringer Ingelheim, Canadian Medical and Surgical Knowledge, Emcure Pharma, Eris Lifesciences, European Academy of CME, Hikma Pharmaceuticals, Imagica Health, Intas Pharma, J.B. Chemicals and Pharma, Lupin Pharma, Medscape/theheart.org, ProAdWise Communications, Radcliffe Cardiology, Sun Pharma, The Corpus, Translation Research Group and Translational Medicine Academy; and is a director of Global Clinical Trial Partners. P.L.M. has received research support from AstraZeneca and received consulting fees from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Novartis, Novo Nordisk, Orion Pharma, Pharmacosmos, Sanofi, Us2.ai and Vifor. T.O. has received research support from Abbott Diagnostics, ChromaDex, Novartis and Roche Diagnostics; consulting fees and/or speaker honoraria from Abbott Diagnostics, Bayer, CardiNor and Roche Diagnostics; and stock and stock options from CardiNor.